-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendis Pharma’s TransCon CNP Wins CHMP Backing for Pediatric Achondroplasia

PUBT·10/17/2026 13:53:09
Listen to the news
Ascendis Pharma’s TransCon CNP Wins CHMP Backing for Pediatric Achondroplasia
  • EMA’s CHMP recommended Ascendis Pharma’s once-weekly TransCon CNP for achondroplasia in children aged 2 and older with open growth plates.
  • A European Commission decision is expected in the fourth quarter of 2026.
  • Subject to approval, the first EU launch under the YUVIWEL brand is planned in Germany for the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610170952OMX_____CNEWS_DE_GNW9847835_de) on October 17, 2026, and is solely responsible for the information contained therein.